XVIVO

XVIVO is a global leader in organ preservation and perfusion technologies, focused on enhancing outcomes in organ transplantation for lungs, hearts, livers, and kidneys. Founded in 1998, the company has a strong history of innovation, beginning with the acquisition of PERFADEX®, a key solution in lung transplant preservation. XVIVO aims to extend the life of donor organs and increase their utilization, ultimately reducing waitlist mortality worldwide. The company offers a range of clinically proven technologies, including PERFADEX® Plus for lung transplantation, a pioneering preservation technology for hearts, and Liver Assist™ for liver preservation. For kidney transplantation, XVIVO provides Kidney Assist™ and Kidney Assist Transport™ devices. Additionally, XVIVO supports thoracic transplant programs through its Organ Recovery Service, which includes on-site organ assessment and logistics for efficient organ procurement. With a customer base that includes over 90% of lung transplantation clinics, XVIVO is committed to improving transplant success rates and patient outcomes globally.

• Employees 190
• Founded 1998
• Annual Revenue $75000000